Sotagliflozin Shows Consistent Heart Failure Benefit Across Blood Pressure Levels
LXRX has more than doubled off its 52-week low of $1.03.
Summary
Lexicon presented a post hoc analysis of the Phase 3 SOLOIST-WHF trial at ESC Congress 2026, showing sotagliflozin reduced cardiovascular death and heart failure events consistently across baseline systolic blood pressure levels. In the lowest blood pressure subgroup (SBP <110 mmHg), the hazard ratio was 0.56 (p=0.03), with no increase in hypotension or acute kidney injury. This is the first report of these data, which were simultaneously published in JACC: Heart Failure. The results strengthen the case for sotagliflozin in a high-risk heart failure population and support its potential label expansion. The company is also advancing sotagliflozin in the Phase 3 SONATA-HCM study for hypertrophic cardiomyopathy, with top-line data expected in 2027.
At the time of this announcement, LXRX was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $1.03 to $2.68. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.